DFine's STAR Spinal Tumor Ablation System To Hit U.S. Market In Q4
This article was originally published in The Gray Sheet
Executive Summary
DFine plans to begin a gradual commercial launch late this year of its STAR system, designed to help cancer patients suffering from painful metastases in the spine.
You may also be interested in...
New Products In Brief
The latest product approvals and launches.
Research In Brief
AF ablation: intracranial impact?
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.